- Home
- CEPO vs GOSS Comparison
CEPO vs GOSS Comparison
Compare CEPO & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEPO
- GOSS
- Stock Information
- Founded
- CEPO 2020
- GOSS 2015
- Country
- CEPO United States
- GOSS United States
- Employees
- CEPO N/A
- GOSS N/A
- Industry
- CEPO
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- CEPO
- GOSS Health Care
- Exchange
- CEPO NYSE
- GOSS Nasdaq
- Market Cap
- CEPO 300.4M
- GOSS 262.5M
- IPO Year
- CEPO 2025
- GOSS 2019
- Fundamental
- Price
- CEPO $11.75
- GOSS $1.38
- Analyst Decision
- CEPO
- GOSS Strong Buy
- Analyst Count
- CEPO 0
- GOSS 3
- Target Price
- CEPO N/A
- GOSS $7.33
- AVG Volume (30 Days)
- CEPO 207.4K
- GOSS 2.5M
- Earning Date
- CEPO 01-01-0001
- GOSS 08-11-2025
- Dividend Yield
- CEPO N/A
- GOSS N/A
- EPS Growth
- CEPO N/A
- GOSS N/A
- EPS
- CEPO 0.10
- GOSS N/A
- Revenue
- CEPO N/A
- GOSS $124,590,000.00
- Revenue This Year
- CEPO N/A
- GOSS N/A
- Revenue Next Year
- CEPO N/A
- GOSS $91.14
- P/E Ratio
- CEPO $123.01
- GOSS N/A
- Revenue Growth
- CEPO N/A
- GOSS N/A
- 52 Week Low
- CEPO $10.04
- GOSS $0.66
- 52 Week High
- CEPO $13.00
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- CEPO N/A
- GOSS 61.04
- Support Level
- CEPO N/A
- GOSS $1.20
- Resistance Level
- CEPO N/A
- GOSS $1.39
- Average True Range (ATR)
- CEPO 0.00
- GOSS 0.09
- MACD
- CEPO 0.00
- GOSS 0.00
- Stochastic Oscillator
- CEPO 0.00
- GOSS 82.91
About CEPO CANTOR EQUITY PARTNERS I INC
Cantor Equity Partners I Inc is a blank check company.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.